Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1R agonist DMB supports in vitro and in vivo investigation of incretin biology
The pill formulation provides a convenient alternative to injectable therapies and was commercially launched in the United States in early 2026, expanding treatment accessibility in the rapidly growing obesity and metabolic disease therapeutics market
GLP-1RAs can downregulate the expression of the myostatin gene in C2C12 myotubes, reversing the upregulation of atrophy factors and downregulation of myogenic factors (MyoD/G) (136)
Given that the average adult has about 5 liters of blood, we can estimate that the bloodstream only holds approximately 5 grams of glucose
US$ 20.07
US$ 26.74
US$ 21.35
US$ 28.28
